|
ÆÊÄ¿³ØÆà |
[±¹³»CRO] ÀÇ·á±â±â PM
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
05.31 |
04.17 |
|
|
ÆÊÄ¿³ØÆà |
[´ë±â¾÷ Á¦¾à»ç] ÀÓ»óÆÀ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
05.31 |
04.25 |
|
|
ÆÊÄ¿³ØÆà |
[±Û·Î¹ú Á¦¾à»ç] ÀÓ»óÆÀ SCRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
05.31 |
04.24 |
|
|
ÆÊÄ¿³ØÆà |
[»óÀå¹ÙÀÌ¿À»ç] ÀÓ»óPM (°úÀå-ºÎÀå±Þ)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
05.31 |
04.02 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[´ë±â¾÷ÀÚȸ»ç] ÀÓ»ó PM 5~6³â
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
06.01 |
04.02 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[¹ÙÀÌ¿À»ç] ÇØ¿ÜÀÓ»ó PM ÆÀ¿ø±Þ
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
06.02 |
05.02 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[À¯¸íÁ¦¾à»çÀÚȸ»ç] ÀÓ»óÆÀÀå Â÷Àå±Þ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
10³â¡è |
06.02 |
05.02 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[ÄÚ½º´Ú»óÀå»ç] ÀÓ»ó°³¹ßÆÀ¿ø/ °¼
¼¿ï °¼±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
06.02 |
05.02 |
|
|
HRKorea |
PV(Pharmacovigilance) ´ã´çÀÚ Ã¤¿ë - ÀÓ»ó½ÃÇè SAE Handlin
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
07.31 |
11.07 |
|
|
HRKorea |
CPM (Clinical Project Manager) ´ã´çÀÚ Ã¤¿ë - ÀÓ»ó °³¹ß
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
07.31 |
11.07 |
|
|
HRKorea |
Biometrics ´ã´çÀÚ Ã¤¿ë - ÀÓ»ó°³¹ß Àü·« ±âȹ, CRO °ü¸® °¨
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
07.31 |
11.07 |
|
|
HRKorea |
ÀÓ»ó°³¹ßÆÀ PMS ÆÄÆ®¿ø(1¸í) - IRB Á¦Ãâ¹®¼ ±¸ºñ ¹× ½ÉÀÇ
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
12.31 |
04.05 |
|
|
HRKorea |
º¸Åø¸®´® Åå½Å PM(Product Manager) - º¸Åø¸®´® Åå½Å ÇÁ¸®¸¶
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
12.31 |
02.19 |
|
|
K1partners |
[±¹³» À¯¸Á¹ÙÀÌ¿Àȸ»ç] CRAä¿ë(¸ð´ÏÅ͸µ ¾øÀ½. CRO °ü¸®,
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
01.17 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
»óÀåÁ¦¾à»ç ÀÓ»óPV(»ç¿ø~´ë¸®±Þ)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
12.29 |
|